Market Overview:
The global biologics contract development and manufacturing organization (CDMO) market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing demand for biologics drugs, rising number of approvals for biosimilars, and growing investments by pharmaceutical companies in contract manufacturing services. The global biologics CDMO market is segmented on the basis of type into biologic contract development services and biologic contract manufacturing services. The Contract Development Services (CDS) segment is expected to grow at a higher CAGR during the forecast period as compared to Contract Manufacturing Services (CMS) due to the increasing demand for complex molecules such as monoclonal antibodies, recombinant proteins, and vaccines. On the basis of application, the global biologics CDMO market is divided into Big Pharma, Small Pharma, Generic Pharma, and Other segments.
 Industry Outlook.svg)
Product Definition:
A biologics contract development and manufacturing organization (CDMO) is a company that provides outsourced services for the development and manufacturing of biologic drugs. CDMOs offer a wide range of services, from early-stage research and development to large-scale production. They can be invaluable resources for companies that lack the expertise or resources to develop or produce their own biologic therapies.
Biologics Contract Development Services:
Biologics CDMO market is expected to grow at a lucrative rate during the forecast period. The primary factor responsible for this growth is the rising demand for biologics and increasing R&D activities in pharmaceuticals.
The global Biologics Contract Development Services, also known as Bio-CDMO or biological contract development services market size was valued at USD 2,15 billion in 2015 and is projected to grow with CAGR of XX% over the forecast period.
Biologics Contract Manufacturing Services:
Biologics Contract Development and Manufacturing Organization (CDMO) is a type of contract development and manufacturing organization that develops biologics products for clients. It offers complete services from cell line development to finished product packaging, labeling, and distribution.
Application Insights:
The other application segment includes vaccines and therapeutics. The other segment held the largest share of over 50% in 2017. This is due to the increasing adoption of advanced technologies such as recombinant DNA and protein engineering for drug development, which has resulted in an increased number of novel products entering clinical trials.
For instance, GlycAideDX is a recombinant human insulin (rh insulin) developed by Pfizer that entered phase 3 clinical trial in 2014 for type 2 diabetes treatment. Similarly, another example is Cosentyx being developed by Genome Canada Inc., which was approved by U.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical manufacturers coupled with the high adoption rate of new technologies is one major factor responsible for its continued dominance over the forecast period. Furthermore, growing R&D expenditure by North American big pharma companies to support their competitive advantage is expected to drive this regional market further. Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to increasing FDI and cross-border investments by multinational players as well as public-private partnerships between governments and industry participants in countries such as China, India, Singapore and Japan are driving this regional market.
Moreover, an increase in demand for generic drugs due to regulatory changes that have relaxed restrictions on price variation across different therapeutic categories has led generic drug manufacturers based outsource production activities overseas thereby boosting overall revenue generation within this region.
Growth Factors:
- Increasing demand for biologics from the pharmaceutical and biotechnology industries
- Growing number of biologic drugs in development
- Rising incidence of chronic diseases
- Technological advancements in the field of biologics manufacturing
- Stringent regulatory environment for drug approvals
Scope Of The Report
Report Attributes
Report Details
Report Title
Biologics Contract Development and Manufacturing Organization(CDMO) Market Research Report
By Type
Biologics Contract Development Services, Biologics Contract Manufacturing Services
By Application
Big Pharma, Small Pharma, Generic Pharma, Other
By Companies
Lonza, Hansen, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, Samsung BioLogics, AGC Biologics, Catalent, Wuxi Biologics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Report Segments:
The global Biologics Contract Development and Manufacturing Organization(CDMO) market is segmented on the basis of:
Types
Biologics Contract Development Services, Biologics Contract Manufacturing Services
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Big Pharma, Small Pharma, Generic Pharma, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lonza
- Hansen
- Boehringer Ingelheim BioXcellence
- Thermo Fisher Scientific
- Samsung BioLogics
- AGC Biologics
- Catalent
- Wuxi Biologics
 Market Overview.svg)
Highlights of The Biologics Contract Development and Manufacturing Organization(CDMO) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biologics Contract Development Services
- Biologics Contract Manufacturing Services
- By Application:
- Big Pharma
- Small Pharma
- Generic Pharma
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biologics Contract Development and Manufacturing Organization(CDMO) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A biologics contract development and manufacturing organization (CDMO) is a type of healthcare business that helps pharmaceutical companies develop, manufacture, and market biologic products. CDMOs typically have expertise in drug development, regulatory affairs, quality control, and manufacturing. They can also provide support services such as clinical trials management or product marketing.
Some of the key players operating in the biologics contract development and manufacturing organization(cdmo) market are Lonza, Hansen, Boehringer Ingelheim BioXcellence, Thermo Fisher Scientific, Samsung BioLogics, AGC Biologics, Catalent, Wuxi Biologics.
The biologics contract development and manufacturing organization(cdmo) market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Biologics Contract Development and Manufacturing Organization(CDMO) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Biologics Contract Development and Manufacturing Organization(CDMO) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Biologics Contract Development and Manufacturing Organization(CDMO) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Biologics Contract Development and Manufacturing Organization(CDMO) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Size & Forecast, 2018-2028
4.5.1 Biologics Contract Development and Manufacturing Organization(CDMO) Market Size and Y-o-Y Growth
4.5.2 Biologics Contract Development and Manufacturing Organization(CDMO) Market Absolute $ Opportunity
Chapter 5 Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Type
5.2.1 Biologics Contract Development Services
5.2.2 Biologics Contract Manufacturing Services
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Applications
6.2.1 Big Pharma
6.2.2 Small Pharma
6.2.3 Generic Pharma
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Biologics Contract Development and Manufacturing Organization(CDMO) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Biologics Contract Development and Manufacturing Organization(CDMO) Analysis and Forecast
9.1 Introduction
9.2 North America Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Type
9.6.1 Biologics Contract Development Services
9.6.2 Biologics Contract Manufacturing Services
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Applications
9.10.1 Big Pharma
9.10.2 Small Pharma
9.10.3 Generic Pharma
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Biologics Contract Development and Manufacturing Organization(CDMO) Analysis and Forecast
10.1 Introduction
10.2 Europe Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Type
10.6.1 Biologics Contract Development Services
10.6.2 Biologics Contract Manufacturing Services
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Applications
10.10.1 Big Pharma
10.10.2 Small Pharma
10.10.3 Generic Pharma
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Biologics Contract Development and Manufacturing Organization(CDMO) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Type
11.6.1 Biologics Contract Development Services
11.6.2 Biologics Contract Manufacturing Services
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Applications
11.10.1 Big Pharma
11.10.2 Small Pharma
11.10.3 Generic Pharma
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Biologics Contract Development and Manufacturing Organization(CDMO) Analysis and Forecast
12.1 Introduction
12.2 Latin America Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Type
12.6.1 Biologics Contract Development Services
12.6.2 Biologics Contract Manufacturing Services
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Applications
12.10.1 Big Pharma
12.10.2 Small Pharma
12.10.3 Generic Pharma
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Biologics Contract Development and Manufacturing Organization(CDMO) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Type
13.6.1 Biologics Contract Development Services
13.6.2 Biologics Contract Manufacturing Services
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Biologics Contract Development and Manufacturing Organization(CDMO) Market Size Forecast by Applications
13.10.1 Big Pharma
13.10.2 Small Pharma
13.10.3 Generic Pharma
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Biologics Contract Development and Manufacturing Organization(CDMO) Market: Competitive Dashboard
14.2 Global Biologics Contract Development and Manufacturing Organization(CDMO) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Lonza
14.3.2 Hansen
14.3.3 Boehringer Ingelheim BioXcellence
14.3.4 Thermo Fisher Scientific
14.3.5 Samsung BioLogics
14.3.6 AGC Biologics
14.3.7 Catalent
14.3.8 Wuxi Biologics
